Skip to main content

Research Repository

Advanced Search

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer

Robertson, John F.R.; Cheung, Kwok-Leung; Noguchi, Shinzaburo; Shao, Zhimin; Degboe, Arnold; Lichfield, Jasmine; Thirlwell, Jackie; Fazal, Mehdi; Ellis, Matthew J.

Authors

Shinzaburo Noguchi

Zhimin Shao

Arnold Degboe

Jasmine Lichfield

Jackie Thirlwell

Mehdi Fazal

Matthew J. Ellis



Abstract

Background
The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC). Furthermore, overall health-related quality of life (HRQoL) was maintained and comparable for fulvestrant and anastrozole. Here, we present additional analyses of patient-reported HRQoL outcomes from FALCON.

Methods
Women with endocrine therapy-naïve HR+ LA/MBC were randomised 1:1 to fulvestrant (days 0, 14, 28, then every 28 d) or anastrozole (daily) until disease progression or discontinuation. HRQoL was assessed by FACT-B questionnaire (TOI and FACT-B total score) at randomisation and every 12 weeks during treatment. HRQoL data post-treatment (with or without progression) were also collected.

Results
In total, 462 patients were randomised (fulvestrant, n = 230; anastrozole, n = 232). Compliance to FACT-B overall ranged from 60.0 to 97.4%. Mean change from baseline in TOI and FACT-B total score remained broadly stable (approximately ± 3 points to week 132) and was similar between arms during treatment. HRQoL was also maintained in FACT-B subscales. Approximately one-third of patients had improved TOI (≥+6 points) and FACT-B (≥+8 points) total scores from baseline up to week 120 and 132, respectively, of treatment with fulvestrant (ranges 26.4–45.0% and 22.4–35.8%, respectively) and anastrozole (ranges 18.6–32.9%, and 22.7–37.9%, respectively).

Conclusions
Mean change from baseline in TOI and FACT-B total score was maintained for fulvestrant and anastrozole; similar proportions of patients in both arms had improved TOI and FACT-B total scores.

Journal Article Type Article
Publication Date May 31, 2018
Journal European Journal of Cancer
Print ISSN 0959-8049
Electronic ISSN 0959-8049
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 94
APA6 Citation Robertson, J. F., Cheung, K., Noguchi, S., Shao, Z., Degboe, A., Lichfield, J., …Ellis, M. J. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 94, https://doi.org/10.1016/j.ejca.2018.02.026
DOI https://doi.org/10.1016/j.ejca.2018.02.026
Keywords Anastrozole; FALCON; Fulvestrant; Health-related quality of life; Locally advanced or metastatic breast cancer
Publisher URL http://www.ejcancer.com/article/S0959-8049(18)30233-8/fulltext
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0

Files

Robertson_FALCON HRQoL manuscript_revised_14Feb2018clean (edited) (accepted version).pdf (158 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0





You might also like



Downloadable Citations

;